Merck KGaA (MKGAF)
(Delayed Data from OTC)
$163.50 USD
-1.50 (-0.91%)
Updated Jul 9, 2024 09:30 AM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MKGAF 163.50 -1.50(-0.91%)
Will MKGAF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MKGAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MKGAF
Here's What Could Help Merck KGaA (MKGAF) Maintain Its Recent Price Strength
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
MKGAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
Other News for MKGAF
Merck KGaA falls after discontinuing head and neck cancer therapy
J.P. Morgan’s top picks within Defensives
Emerging and Chinese pharmas playing greater role in oncology drug development
Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript
Merck KGaA Non-GAAP EPS of €2.06, revenue of €5.12B; updates FY24 outlook